Barr profit down 21% as it nears Teva merger

1 December 2008

The USA's Barr Pharmaceuticals reported third-quarter 2008 profit down 21% compared to the same period of 2007, despite higher revenues, as it prepares to be acquired by Israeli generics giant Teva.

Revenue jumped 22% to $737.0 million, including $562.0 million from sales of generic drugs, an increase of 29%, and $133.0 million from branded products, rising 6%. R&D costs were up 11% to $69.0 million.

Net income, however, dropped to $31.0 million, or $0.28 per share, versus $39.0 million, or $0.36 per share. Still the firm increased its cash and cash equivalents to $587.0 million vs just $246.0 million.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight